Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer
-Study Results Show 100-Fold More Radiation Delivered to Tumor as Compared to Other Organs-
-All Patients Surpassed Expected Median Survival Time at Lowest Planned Dose Level-<img src="http://feeds.foxbusiness.com/~r/foxbusiness/latest/~4/301818761" height="1" width="1"/><img src="http://feeds.foxnews.com/~r/foxnews/business/~4/301821505" height="1" width="1"/>
http://feeds.foxnews.com/~r/foxnews/business/~3/301821505/